Literature DB >> 2421757

The Wiskott-Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes.

G Marone, F Albini, L di Martino, S Quattrin, S Poto, M Condorelli.   

Abstract

Platelets, basophils and neutrophils from a patient with the Wiskott-Aldrich syndrome (WAS) were exposed to stimuli that activate specific membrane receptor or directly initiate biochemical events (e.g. the Ca2+ ionophore A23187 and ionomycin or arachidonic acid). Platelets from this patient did not aggregate in response to ADP, collagen, thrombin or adrenaline, which activate specific membrane receptors. Platelet aggregation, however, was normal in response to compound A23187, ionomycin or exogenous arachidonic acid. Histamine release from basophils of the WAS patient was normal in response to anti-IgE, a formylated peptide (f-met peptide), and to A23187. Similarly, the release of the lysosomal enzymes, beta-glucuronidase and lysozyme, from neutrophils of the WAS patient in response to serum treated zymosan (Zx), f-met peptide, and A23187 was not significantly different from that of his parents and 13 normal donors. These results suggest that the primary defect in WAS is selectively present in platelets and is located in a biochemical step between receptor activation and Ca2+ influx and/or initiation of arachidonate metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421757     DOI: 10.1111/j.1365-2141.1986.tb04097.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome.

Authors:  J Litzman; A Jones; I Hann; H Chapel; S Strobel; G Morgan
Journal:  Arch Dis Child       Date:  1996-11       Impact factor: 3.791

Review 2.  The thrombocytopenia of WAS: a familial form of ITP?

Authors:  Ted S Strom
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.

Authors:  Anja J Gerrits; Emily A Leven; Andrew L Frelinger; Sophie L Brigstocke; Michelle A Berny-Lang; W Beau Mitchell; Shoshana Revel-Vilk; Hannah Tamary; Sabrina L Carmichael; Marc R Barnard; Alan D Michelson; James B Bussel
Journal:  Blood       Date:  2015-07-29       Impact factor: 22.113

4.  Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes.

Authors:  J Zhang; A Shehabeldin; L A da Cruz; J Butler; A K Somani; M McGavin; I Kozieradzki; A O dos Santos; A Nagy; S Grinstein; J M Penninger; K A Siminovitch
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

Review 5.  Platelets: still a therapeutical target for haemostatic disorders.

Authors:  Reinaldo Barros Geraldo; Plínio Cunha Sathler; André Luiz Lourenço; Max Seidy Saito; Lucio M Cabral; Pabulo Henrique Rampelotto; Helena Carla Castro
Journal:  Int J Mol Sci       Date:  2014-10-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.